Table 5 Follow up results of the studied patients
Pre TIMI | Test value | P value | Sig | ||
|---|---|---|---|---|---|
TIMI (0) | TIMI (I–III) | ||||
No. = 93 | No. = 57 | ||||
Initial EF (%) | |||||
Mean ± SD | 43.87 ± 8.57 | 47.05 ± 7.55 | − 2.305• | 0.023 | S |
Range | 20–75 | 30–63 | |||
Hospital stay (days) | |||||
Mean ± SD | 3.66 ± 0.97 | 3.40 ± 1.02 | 1.522• | 0.130 | NS |
Range | 2–6 | 2–8 | |||
In-hospital MACE | |||||
Negative | 80 (86.0%) | 54 (94.7%) | 2.817* | 0.093 | NS |
Mortality | 7 (7.5%) | 0 (0.0%) | 4.500* | 0.033 | S |
TLR | 0 (0.0%) | 0 (0.0%) | NA | NA | NA |
HF admission | 6 (6.5%) | 2 (3.5%) | 0.606* | 0.436 | NS |
CABG | 0 (0.0%) | 1 (1.8%) | 1.643* | 0.199 | NS |
TIA | 0 (0.0%) | 0 (0.0%) | NA | NA | NA |
Follow up EF (%) | |||||
Mean ± SD | 45.42 ± 9.27 | 50.12 ± 7.69 | − 3.193• | 0.002 | HS |
Range | 22–70 | 30–65 | |||
MACE FUP | |||||
Negative | 67 (72.0%) | 54 (94.7%) | 11.670* | 0.000 | HS |
Mortality | 12 (12.9%) | 0 (0.0%) | 7.994* | 0.005 | HS |
TLR | 8 (8.6%) | 3 (5.3%) | 0.580* | 0.446 | NS |
HF admission | 4 (4.3%) | 0 (0.0%) | 2.519* | 0.112 | NS |
CABG | 1 (1.1%) | 0 (0.0%) | 0.617* | 0.432 | NS |
TIA | 1 (1.1%) | 0 (0.0%) | 0.617* | 0.432 | NS |